Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies
Serum Interleukin-6 is Not Linked with Sleep-Quality, Restless Legs Syndrome, and Depression, But with 6-Month Survival in Hematological Malignancies
复制标题
DOI：
10.4103/jnrp.jnrp_159_18
复制
发表时间：
2019-01-01
影响因子：
1.4
通讯作者：
Gupta, Ravi
中科院分区：
文献类型：
--
作者：
Chandra, Smita;Gupta, Vibha;Gupta, Ravi
背景：血清白细胞介素（IL）-6与实体瘤患者的睡眠质量、情绪和生存率相关。这些研究的结果受到研究受试者诊断知识的混淆。此外，血液恶性肿瘤受试者的此类数据和有关不宁腿综合征的数据有限。本研究，因此，进行评估的睡眠质量，抑郁症，不宁腿综合征的血液恶性肿瘤和研究，如果有任何作用的IL 6与it. Methods：66例血液恶性肿瘤被列入本研究后，排除潜在的混杂因素。睡眠质量采用睡眠质量指数，抑郁采用患者健康问卷-9。RLS的诊断通过临床检查作出。在基线和开始化疗1个月后收集用于测量IL-6的血清。术后随访6个月。结果：研究对象的平均年龄为50.16岁，男性居多。近22.7%有临床抑郁症，28.8%有睡眠质量差，6.1%的病例报告有不宁腿综合征（RLS）。近22.7%的患者在6个月内死亡。基线睡眠障碍与抑郁症（比值比[OR] = 7.89）和6个月生存率差相关。血清IL-6与睡眠质量、不宁腿综合征和抑郁症无相关性。而化疗前血清IL-6水平高（OR = 26.06）和化疗后血清IL-6水平低（OR = 0.03）与6个月生存率低相关。结论：睡眠质量差、抑郁和RLS在成人血液系统恶性肿瘤患者中普遍存在。睡眠障碍、化疗前高炎症和化疗后炎症负荷降低增加了预后不良的可能性。血清IL-6与睡眠质量、不宁腿综合征和抑郁症无相关性。
Background: Serum interleukin (IL) -6 has been found to be associated with sleep quality, mood, and survival in patients with solid tumors. Results in these studies were confounded by knowledge of diagnosis to study subjects. Moreover, such data among subjects with hematological malignancies and data regarding restless legs syndrome is limited. The present study was, therefore, conducted to assess the sleep quality, depression, and restless leg syndrome in hematological malignancies and to study if there is any role of IL6 associated with it. Methods: Sixty-six subjects having hematological malignancy were included in this study after excluding the potential confounders. Sleep quality was examined using Pittsburg Sleep Quality Index, depression by the Patient Health Questionnaire-9. Diagnosis of RLS was made through clinical examination. Serum for measurement of IL-6 was collected at baseline and after 1 month of initiation of chemotherapy. Patients were followed up for 6 months. Results: Average age of study subjects was 50.16 years with male predominance. Nearly 22.7% had clinical depression, 28.8% had poor quality sleep, and restless legs syndrome (RLS) was reported in 6.1% cases. Nearly 22.7% patients died at 6 months. Disturbed sleep at baseline was associated with depression (odds ratio [OR] = 7.89) and poor 6 months survival. Serum IL-6 did not show any association with sleep quality, restless-legs-syndrome, and depression. However, baseline high level of serum IL-6 (OR = 26.06) and low level after chemotherapy (OR = 0.03) were associated with poor survival at 6 months. Conclusion: Poor quality sleep, depression, and RLS are prevalent among adult subjects with hematological malignancies. Sleep disturbance, high pretreatment inflammatory and lowering of inflammatory load after chemotherapy increase likelihood for poor prognosis. Serum IL-6 did not show any association with sleep quality, restless legs syndrome and depression.